Javascript must be enabled to continue!
Bleeding in neonates with severe thrombocytopenia: a retrospective cohort study
View through CrossRef
Abstract
Background
Severe neonatal thrombocytopenia is a rare disease with multiple etiologies. Severe thrombocytopenia with bleeding is life-threatening and has attracted significant attention from clinicians. However, only a few studies have focused on the association between severe thrombocytopenia and bleeding. Thus, this study aimed to describe the neonates’ postnatal age at which severe thrombocytopenia was first recognized, clinical characteristics, bleeding patterns, and outcomes and to evaluate the association between minimum platelet count and bleeding.
Methods
A single-center retrospective cohort study for neonates with severe thrombocytopenia (platelet count ≤ 50 × 109/L) was conducted. Neonates who were admitted to our neonatal intensive care unit between October 2016 and February 2021 and developed severe thrombocytopenia were analyzed. Data were collected retrospectively until the patients were referred to other hospitals, discharged, or deceased.
Results
Among the 5819 neonatal inpatients, 170 with severe thrombocytopenia were included in this study. More than 30% of the patients had severe thrombocytopenia in the first 3 days of life. Among the 118 neonates with bleeding, 47 had more than one type of pathological bleeding. Neonates with very severe thrombocytopenia (point estimate: 53.7%, 95% confidence interval [CI]: 44.2%–63.1%) had a higher incidence rate of cutaneous bleeding than those with severe thrombocytopenia (point estimate: 23.4%, 95% CI: 12.3%–34.4%). The gestational age (median: 36.2 [interquartile range [IQR]: 31.4–39.0] weeks) and birth weight (median: 2310 [IQR: 1213–3210] g) of the major bleeding group were the lowest among no bleeding, minor bleeding, and major bleeding groups. Regression analysis controlled for confounders and confirmed that a lower platelet count (odds ratio [OR]: 2.504 [95% CI: 1.180–5.314], P = 0.017) was associated with a significant increase in the rate of bleeding. Very severe thrombocytopenia (point estimate: 49.1%, 95% CI: 39.6%–58.6%) had a higher rate of platelet transfusion than severe thrombocytopenia (point estimate: 5.7%, 95% CI: 0.7%–10.7%). The mortality rate was higher in neonates with bleeding than in those without bleeding (point estimates with 95% CI: 33.1% [24.4%–41.7%] vs. 7.7% [0.2%–15.2%]).
Conclusions
These findings describe the incidence of severe thrombocytopenia and demonstrate that a lower platelet count is associated with an increased bleeding rate in patients with severe thrombocytopenia.
Springer Science and Business Media LLC
Title: Bleeding in neonates with severe thrombocytopenia: a retrospective cohort study
Description:
Abstract
Background
Severe neonatal thrombocytopenia is a rare disease with multiple etiologies.
Severe thrombocytopenia with bleeding is life-threatening and has attracted significant attention from clinicians.
However, only a few studies have focused on the association between severe thrombocytopenia and bleeding.
Thus, this study aimed to describe the neonates’ postnatal age at which severe thrombocytopenia was first recognized, clinical characteristics, bleeding patterns, and outcomes and to evaluate the association between minimum platelet count and bleeding.
Methods
A single-center retrospective cohort study for neonates with severe thrombocytopenia (platelet count ≤ 50 × 109/L) was conducted.
Neonates who were admitted to our neonatal intensive care unit between October 2016 and February 2021 and developed severe thrombocytopenia were analyzed.
Data were collected retrospectively until the patients were referred to other hospitals, discharged, or deceased.
Results
Among the 5819 neonatal inpatients, 170 with severe thrombocytopenia were included in this study.
More than 30% of the patients had severe thrombocytopenia in the first 3 days of life.
Among the 118 neonates with bleeding, 47 had more than one type of pathological bleeding.
Neonates with very severe thrombocytopenia (point estimate: 53.
7%, 95% confidence interval [CI]: 44.
2%–63.
1%) had a higher incidence rate of cutaneous bleeding than those with severe thrombocytopenia (point estimate: 23.
4%, 95% CI: 12.
3%–34.
4%).
The gestational age (median: 36.
2 [interquartile range [IQR]: 31.
4–39.
0] weeks) and birth weight (median: 2310 [IQR: 1213–3210] g) of the major bleeding group were the lowest among no bleeding, minor bleeding, and major bleeding groups.
Regression analysis controlled for confounders and confirmed that a lower platelet count (odds ratio [OR]: 2.
504 [95% CI: 1.
180–5.
314], P = 0.
017) was associated with a significant increase in the rate of bleeding.
Very severe thrombocytopenia (point estimate: 49.
1%, 95% CI: 39.
6%–58.
6%) had a higher rate of platelet transfusion than severe thrombocytopenia (point estimate: 5.
7%, 95% CI: 0.
7%–10.
7%).
The mortality rate was higher in neonates with bleeding than in those without bleeding (point estimates with 95% CI: 33.
1% [24.
4%–41.
7%] vs.
7.
7% [0.
2%–15.
2%]).
Conclusions
These findings describe the incidence of severe thrombocytopenia and demonstrate that a lower platelet count is associated with an increased bleeding rate in patients with severe thrombocytopenia.
Related Results
Bleeding Risk Factors in Thrombocytopenic Patients with Hematologic Malignancies
Bleeding Risk Factors in Thrombocytopenic Patients with Hematologic Malignancies
Introduction
Despite prophylactic platelet transfusions, World Health Organization (WHO) grade ≥ 2 bleeding occurs in 50 to 70% of patients with hematologic malignan...
Frequency of Thrombocytopenia in Malaria and its prognostic significance
Frequency of Thrombocytopenia in Malaria and its prognostic significance
BACKGROUND & OBJECTIVE: Thrombocytopenia is a common hematological manifestation of malaria, but locally there is limited data on the association of thrombocytopenia degree and...
Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial
Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial
Background: Despite optimal prophylactic platelet (plt) transfusion therapy for severe thrombocytopenia in patients undergoing treatment for hematologic malignancy, WHO Grade 2 or ...
Analysis of bleeding outcomes in patients with hypoproliferative thrombocytopenia in the A‐TREAT clinical trial
Analysis of bleeding outcomes in patients with hypoproliferative thrombocytopenia in the A‐TREAT clinical trial
AbstractBackgroundDespite prophylactic platelet transfusions, hypoproliferative thrombocytopenia is associated with bleeding; historical risk factors include hematocrit (HCT) 25%, ...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Demographic and Clinical Data in 118 Acquired Hemophilia a: Results from a Single Center Study
Demographic and Clinical Data in 118 Acquired Hemophilia a: Results from a Single Center Study
Introduction:
Acquired hemophilia A (AHA) is an autoimmune disorder marked by the development of autoantibodies targeting coagulation factor VIII. This rare condi...
Does Gender Affect Levels of Hyperbilirubinemia in Term Neonates
Does Gender Affect Levels of Hyperbilirubinemia in Term Neonates
Introduction: Hyperbilirubinemia is a common & in most1cases, benign problem in1first month of1life which is often1physiologic & intervention is not1usually1necessary. In t...
Association of Anticoagulant Therapy with Bleeding in Patients with Chronic Liver Disease: A Case-Cross over Study Using the National Veterans Health Administration Database
Association of Anticoagulant Therapy with Bleeding in Patients with Chronic Liver Disease: A Case-Cross over Study Using the National Veterans Health Administration Database
Background:
Patients with chronic liver disease (CLD) are at a higher risk of venous thromboembolism (VTE) i.e., deep venous thrombosis or pulmonary embolism {Amb...


